A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Clinical trial NCT04586231 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04586231
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma, Renal Cell

Start date: 2021-02-25
Primary completion: 2026-02-02
Enrollment: 747

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.